Analysts are recommending to “buy” Mapletree North Asia Commercial Trust (MNACT) despite a rather disappointing set of 1HFY2021 results, as a glimmer of hope emerges with the trust’s gradual improvement.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply